Literature DB >> 17945195

Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys.

Glenn T Konopaske1, Karl-Anton Dorph-Petersen, Robert A Sweet, Joseph N Pierri, Wei Zhang, Allan R Sampson, David A Lewis.   

Abstract

BACKGROUND: Both in vivo and postmortem studies suggest that oligodendrocyte and myelination alterations are present in individuals with schizophrenia. However, it is unclear whether prolonged treatment with antipsychotic medications contributes to these disturbances. We recently reported that chronic exposure of macaque monkeys to haloperidol or olanzapine was associated with a 10%-18% lower glial cell number in the parietal grey matter. Consequently, in this study we sought to determine whether the lower glial cell number was due to fewer oligodendrocytes as opposed to lower numbers of astrocytes.
METHODS: With fluorescent immunocytochemical techniques, we optimized the visualization of each cell type throughout the entire thickness of tissue sections, while minimizing final tissue shrinkage. As a result, we were able to obtain robust stereological estimates of total oligodendrocyte and astrocyte numbers in the parietal grey matter with the optical fractionator method.
RESULTS: We found a significant 20.5% lower astrocyte number with a non-significant 12.9% lower oligodendrocyte number in the antipsychotic-exposed monkeys. Similar effects were seen in both the haloperidol and olanzapine groups.
CONCLUSIONS: These findings suggest that studies investigating glial cell alterations in schizophrenia must take into account the effect of antipsychotic treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17945195      PMCID: PMC2386415          DOI: 10.1016/j.biopsych.2007.08.018

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  40 in total

1.  S100beta interaction with tau is promoted by zinc and inhibited by hyperphosphorylation in Alzheimer's disease.

Authors:  W H Yu; P E Fraser
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

2.  Normal development of serotonergic neurons in mice lacking S100B.

Authors:  Hiroshi Nishiyama; Masaaki Takemura; Takehiro Takeda; Shigeyoshi Itohara
Journal:  Neurosci Lett       Date:  2002-03-15       Impact factor: 3.046

3.  Tissue shrinkage and unbiased stereological estimation of particle number and size.

Authors:  K A Dorph-Petersen; J R Nyengaard; H J Gundersen
Journal:  J Microsc       Date:  2001-12       Impact factor: 1.758

Review 4.  Transfer of glutamine between astrocytes and neurons.

Authors:  S Bröer; N Brookes
Journal:  J Neurochem       Date:  2001-05       Impact factor: 5.372

5.  Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain.

Authors:  Martha S Windrem; Neeta S Roy; Jeremy Wang; Marta Nunes; Abdellatif Benraiss; Robert Goodman; Guy M McKhann; Steven A Goldman
Journal:  J Neurosci Res       Date:  2002-09-15       Impact factor: 4.164

Review 6.  Pathophysiologically based treatment interventions in schizophrenia.

Authors:  David A Lewis; Guillermo Gonzalez-Burgos
Journal:  Nat Med       Date:  2006-09       Impact factor: 53.440

Review 7.  The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer.

Authors:  Lasse K Bak; Arne Schousboe; Helle S Waagepetersen
Journal:  J Neurochem       Date:  2006-06-19       Impact factor: 5.372

8.  Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia.

Authors:  Y Hakak; J R Walker; C Li; W H Wong; K L Davis; J D Buxbaum; V Haroutunian; A A Fienberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

9.  Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.

Authors:  P J Perry; B C Lund; T Sanger; C Beasley
Journal:  J Clin Psychopharmacol       Date:  2001-02       Impact factor: 3.153

Review 10.  Cognitive impairment in schizophrenia is the core of the disorder.

Authors:  B Elvevåg; T E Goldberg
Journal:  Crit Rev Neurobiol       Date:  2000
View more
  95 in total

Review 1.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

2.  Fiber geometry in the corpus callosum in schizophrenia: evidence for transcallosal misconnection.

Authors:  Thomas J Whitford; Peter Savadjiev; Marek Kubicki; Lauren J O'Donnell; Douglas P Terry; Sylvain Bouix; Carl-Fredrik Westin; Jason S Schneiderman; Laurel Bobrow; Andrew C Rausch; Margaret Niznikiewicz; Paul G Nestor; Christos Pantelis; Stephen J Wood; Robert W McCarley; Martha E Shenton
Journal:  Schizophr Res       Date:  2011-08-09       Impact factor: 4.939

3.  Predicting inter-hemispheric transfer time from the diffusion properties of the corpus callosum in healthy individuals and schizophrenia patients: a combined ERP and DTI study.

Authors:  Thomas J Whitford; Marek Kubicki; Shahab Ghorashi; Jason S Schneiderman; Kathryn J Hawley; Robert W McCarley; Martha E Shenton; Kevin M Spencer
Journal:  Neuroimage       Date:  2010-10-25       Impact factor: 6.556

4.  [Can long-term treatment with antipsychotic drugs lead to structural brain damage? Against].

Authors:  G Gründer
Journal:  Nervenarzt       Date:  2013-09       Impact factor: 1.214

5.  [Can long-term treatment with antipsychotic drugs lead to structural brain damage? Pro].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2013-09       Impact factor: 1.214

Review 6.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

7.  Cerebral white matter abnormalities and their associations with negative but not positive symptoms of schizophrenia.

Authors:  Takeshi Asami; Sang Hyuk Lee; Sylvain Bouix; Yogesh Rathi; Thomas J Whitford; Margaret Niznikiewicz; Paul Nestor; Robert W McCarley; Martha E Shenton; Marek Kubicki
Journal:  Psychiatry Res       Date:  2014-02-19       Impact factor: 3.222

Review 8.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

9.  Evidence for morphological alterations in prefrontal white matter glia in schizophrenia and bipolar disorder.

Authors:  Christa Hercher; Vikramjit Chopra; Clare L Beasley
Journal:  J Psychiatry Neurosci       Date:  2014-11       Impact factor: 6.186

10.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.